Wa'el Hashad Wa'el Hashad, CEO, Longeveron On-going Phase 2b clinical trial (ELPIS II) deemed pivotal and, if positive, acceptable for Biological License Application (BLA) submission for potential ...
Labeling is based on the agency's thorough analysis of the new drug application (NDA) or biological license application. The labeling, or prescribing information, is thus subject to FDA ...
Republican-led states are increasingly making it difficult for trans people to update their gender marker on state-issued ...
In its latest warning letter, FDA raised concern that the company was still producing eye drops with amniotic fluid, even ...
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report) and keeping the ...
From zero cost to the lack of limitations, the Linux operating system and open-source software may be worth looking into for ...
JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on OPT stock, giving a Buy rating on September 12. Debanjana ...
Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technologyROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif ...
Explore the challenges of ADC characterization, key techniques, and the benefits of partnering with a CDMO for effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback